NAD+ infusions are frequently discussed in relation to energy, recovery and healthy ageing, but interest should not be mistaken for established clinical benefit. This NAD evidence review examines what is known about intravenous NAD+ therapy, where the research is limited, and what responsible assessment should look like before treatment is considered.
What NAD+ does in the body
Nicotinamide adenine dinucleotide, usually referred to as NAD, is a naturally occurring coenzyme found in every living cell. It has essential roles in energy metabolism, cellular signalling and processes involved in DNA repair. NAD+ is the oxidised form of the molecule, while NADH is the reduced form. Cells continuously convert between these forms as part of normal metabolic activity.
NAD levels may change with age, illness, nutritional status and metabolic stress. This biological relevance has led to interest in therapies intended to influence NAD availability. However, a plausible biological mechanism is not the same as evidence that an intervention improves symptoms, prevents disease or extends healthy lifespan in people.
That distinction is particularly important for IV therapy. An infusion can deliver a substance directly into the bloodstream, but it does not automatically show that the substance reaches the relevant tissues, changes cellular function in a meaningful way, or produces outcomes patients can feel and sustain.
What an NAD evidence review can tell us
The evidence base for intravenous NAD+ is still limited. Much of the broader research interest in NAD biology concerns precursors, including nicotinamide riboside and nicotinamide mononucleotide, rather than NAD+ administered by infusion. These are different interventions, with different absorption, metabolism, doses and routes of administration. Findings from one should not be assumed to apply to another.
Some studies of oral NAD precursors have shown that they can alter markers associated with NAD metabolism. This may help researchers understand biochemical effects, but changes in biomarkers do not by themselves establish a clinical benefit. High-quality evidence would need to show meaningful improvements in clearly defined outcomes, such as function, disease-specific symptoms or quality of life, against an appropriate comparison group.
For IV NAD+ specifically, published human research is relatively small and heterogeneous. Studies may differ in dose, infusion rate, participant characteristics, outcome measures and duration of follow-up. Some reports describe tolerability or short-term physiological observations, but there is insufficient high-quality evidence to support broad claims that NAD+ infusions reliably treat fatigue, burnout, addiction, cognitive decline, chronic illness or ageing.
This does not mean that a person cannot report feeling better after an infusion. Individual experience can be influenced by hydration, rest, the clinical setting, expectations, concurrent lifestyle changes and natural variation in symptoms. It is why controlled research is needed before an observed response can be attributed confidently to NAD+ itself.
The difference between mechanism and outcome
A common source of confusion is the leap from laboratory science to patient benefit. NAD-dependent pathways are relevant to metabolism and cellular maintenance, but interventions affecting those pathways may have modest, variable or no measurable effects in real-world clinical use.
Research in cells and animals can identify useful hypotheses. It cannot determine the appropriate dose, safety profile, duration of effect or clinical value for people receiving an IV infusion. Those questions require well-designed human trials with sufficient numbers of participants and transparent reporting of adverse events.
NAD evidence review: where uncertainty remains
Several important questions remain unanswered. There is no widely accepted IV NAD+ protocol supported by strong clinical-outcomes evidence for general wellness, recovery or longevity. The optimal dose and infusion rate are uncertain, as is the frequency of treatment, whether any effect is sustained, and which patients, if any, are most likely to benefit.
There is also limited evidence on longer-term use. A treatment may appear tolerable over one appointment but have a different risk profile when repeated. Studies should assess not only immediate symptoms but also delayed adverse effects, interactions with medicines and outcomes in people with existing medical conditions.
The evidence should also be judged against the reason a person is seeking care. Persistent fatigue, reduced exercise tolerance, brain fog, low mood, sleep disruption or recurrent headaches are not diagnoses. They can have causes ranging from sleep deprivation and nutritional deficiency to endocrine, cardiovascular, neurological or mental health conditions. An IV treatment should not replace appropriate assessment of new, severe or persistent symptoms.
Safety considerations for intravenous NAD+
NAD+ infusions are not risk-free simply because NAD is naturally present in the body. The route of administration introduces procedural risks, including pain or bruising at the cannula site, inflammation of a vein, infiltration or extravasation, infection and, in some circumstances, fluid-related complications.
During NAD+ administration, people may experience symptoms such as nausea, abdominal discomfort, chest tightness, headache, flushing or a sense of breathlessness, particularly if an infusion is given too quickly. These symptoms need prompt clinical assessment rather than being dismissed as an expected part of treatment. Infusion rate, patient monitoring and the ability to respond to deterioration are practical safety issues, not administrative details.
A clinician should take a full medical history, including medicines, allergies, previous infusion reactions and relevant conditions affecting fluid balance or cardiovascular and renal function. Pregnancy and breastfeeding require particular caution because evidence is insufficient to establish safety. The decision to proceed should be individualised, documented and revisited if symptoms or circumstances change.
What good clinical governance looks like
For patients, the quality of clinical oversight matters at least as much as the ingredient being discussed. A responsible service starts with a consultation that explores the person’s goals, symptoms, medical history and whether another form of assessment is more appropriate. It should be clear about the limits of the evidence and should not present NAD+ as a substitute for diagnosis or established medical care.
There should be a named, appropriately qualified clinician accountable for assessment and prescribing decisions where required. Staff administering infusions should be trained and competent in IV practice, infection prevention, recognition of adverse reactions and emergency procedures. The service should use appropriate records, consent processes, product traceability and incident reporting.
In the UK, professional accountability and clinical governance are central considerations. Depending on the service provided, this may include the relevant standards of professional regulators, medicines management processes and, where applicable, Care Quality Commission requirements. Patients should be able to ask who is responsible for their care and receive a straightforward answer.
Questions to ask before considering NAD+ therapy
Before booking an IV NAD+ infusion, it is reasonable to ask what outcome the clinician believes it may support, what evidence is relevant to that specific aim, and what the realistic limitations are. Ask how side effects are managed, whether your medical history changes the risk, and what follow-up is offered if you feel unwell after leaving the clinic.
It is equally reasonable to ask whether a GP review, blood tests or another clinical pathway may be more appropriate for your symptoms. A good provider will not treat these questions as obstacles. They are part of informed consent and safer decision-making.
For healthcare professionals and clinic operators, careful communication is essential. Marketing should distinguish established facts about NAD biology from unproven claims about IV NAD+ outcomes. Records should capture the rationale for treatment, discussion of alternatives, consent, product details, observations during administration and any adverse events.
The most useful question is not whether NAD+ sounds promising, but whether the available evidence justifies it for your individual circumstances. A clinic that communicates uncertainty clearly, assesses you properly and prioritises safety provides a sounder basis for decision-making than one that promises certainty.